D. Boumpas

Cardiology and Cardiovascular Medicine · 2003–2020

A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Cardiology and Cardiovascular Medicine — 15 citations into it
• Public Health, Environmental and Occupational Health — 15 citations into it

Whom D. Boumpas trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Massimo F. Piepoli

Papers from D. Boumpas's perspective

Ordered by how strongly the researchers D. Boumpas trusts endorse each paper. Same corpus, a different order for every researcher.

1. New therapies for treatment of rheumatoid arthritis. (The Lancet)
2. Neuromyelitis optica and non organ-specific autoimmunity. (Archives of Neurology)
3. Sequential therapies for proliferative lupus nephritis. (New England Journal of Medicine)
4. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. (American Journal of Medicine)
5. Syndromes of thrombotic microangiopathy. (New England Journal of Medicine)
6. 2016 European Guidelines on cardiovascular disease prevention in clinical practice (International Journal of Behavioral Medicine)
7. The classification of glomerulonephritis in systemic lupus erythematosus revisited. (Journal of the American Society of Nephrology)
8. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular… (European Journal of Cardiovascular Prevention & Rehabilitation)
9. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. (New England Journal of Medicine)
10. Lipoprotein(a) as a cardiovascular risk factor: current status (European Heart Journal)

Their papers

• 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis (2020) — 719 citations
• Update οn the diagnosis and management of systemic lupus erythematosus (2020) — 599 citations
• 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus (2019) — 1,638 citations
• 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus (2019) — 3,045 citations
• EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome (2015) — 790 citations
• Treat-to-target in systemic lupus erythematosus: recommendations from an international task force (2014) — 688 citations
• Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (2012) — 974 citations
• Treating rheumatoid arthritis to target: recommendations of an international task force (2010) — 2,111 citations
• EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs (2010) — 736 citations
• EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (2007) — 752 citations
• A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. (2003) — 624 citations